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AbstrACt
Africa trails the rest of the world in COVID-19 cases and deaths. However, as the pandemic spreads through the 
continent, we expect increases in community infection in the months ahead. Patients with kidney disease, especially 
those with end-stage kidney disease and those with kidney transplants, are at high risk for acquiring the disease and 
dying from it. While there is limited evidence for the benefit of interventions, we have the advantage of learning 
from the experiences of those in China, Europe and the Americas. This document sets forth guidance for dealing 
with our patients who have acute and chronic kidney disease, including those on renal replacement therapy and the 
staff involved in their care. Emphasis is placed on preparedness and prevention strategies. As evidence and experience 
accumulate, it is likely that updated guidance will be needed.
L’Afrique suit le reste du monde en termes de nombre de cas et de décès dus à COVID-19. Cependant, alors que 
la pandémie se propage à travers le continent, nous prévoyons une augmentation de l’infection communautaire dans 
les mois à venir. Les patients atteints d’une maladie rénale, en particulier ceux atteints d’une maladie rénale chronique 
en phase terminale et ceux ayant subi une transplantation rénale, courent un risque élevé de contracter la maladie 
et d’en mourir. Bien que les preuves d’interventions soient limitées, nous avons l’avantage de tirer des enseignements 
des expériences de ceux qui se trouvent en Chine, en Europe et dans les Amériques. Ce document présente des 
conseils pour traiter nos patients atteints d’insuffisance rénale aiguë et chronique, y compris ceux sous thérapie de 
suppléance rénale et le personnel impliqué dans leurs soins. L’accent est mis sur les stratégies de préparation et de 
prévention. Au fur et à mesure que les preuves et l’expérience s’accumulent, il est probable que des directives 
actualisées seront nécessaires.
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cardiac disease, chronic kidney disease (CKD) and 
patients on immunosuppression [9].
c. Genetic susceptibility or protection is not proven.
d.  Mortality seems lower in Africa, although there is no
proven reason. This may be a false impression as
numbers of infections are still relatively low.
e.  Infection and viral shedding may persist for several
weeks. The implications for infection control remain
unclear. Recent data suggest that it is unlikely that live
virus is shed beyond the second week of infection [10].
2.3.  CKD-related issues
a. Mortality is higher in patients with CKD [11].
b.  Chronic haemodialysis (HD) patients are vulnerable due
to their frequent travel for dialysis, regular contact with
dialysis staff and other patients and multiple comor-
bidities. They also have a higher mortality [12,13].
2.4.  Case definitions
a.  Confirmed case: a person who has tested positive for
the SARS-CoV-2 pathogen in accordance with testing
standards, irrespective of clinical signs and symptoms.
b.  Suspected case: a person who develops a fever ≥ 37.5°C
or respiratory symptoms such as coughing or difficulty
breathing within 14 days of coming into contact with a
confirmed case while that patient was symptomatic.
c.  Contacts: contacts are identified after epidemiological
investigation and include patients who received HD on
the same shift as a confirmed case, patients who received
HD without proper prior disinfection of equipment
after HD of a confirmed case, and patients or healthcare
workers who were exposed (within 2 metres) to a
confirmed case without adequate personal protective
equipment (PPE).
These guidelines draw from international and local 
experience with this disease. As expected in a rapidly 
developing pandemic, there is a paucity of high-quality 
evidence. Individual centres will have to adapt guidance 
provided based on the unique circumstances in their 
countries as well as available resources. 
The International Society of Nephrology (ISN) [12] and 
the European Dialysis and Transplant Association (EDTA) 
[13] have dedicated web pages with collected resources
and recommendations.
3. CHrONIC KIDNEY DIsEAsE [14,15]
Patients with CKD stages 3–5 have been identified as a 
high-risk group for COVID-19 complications. Many have 
hypertension, diabetes and coronary artery disease, which 
are additional risk factors. Many patients are on immuno-
suppression for glomerular or multisystem diseases.
1. INtrODUCtION
COVID-19 is a condition caused by the SARS-CoV-2 
coronavirus. This novel virus has spread around the world 
and has caused significant fatalities in many countries. The 
virus’s impact on health systems and economies has caused 
widespread distress.
On the African continent, the virus has been documented 
in all 47 countries, with almost 85,000 cases and 2,760 
deaths as at 16 May 2020 [1,2]. Public health guidelines 
prepared by various international organizations and 
countries are widely available and give advice to prevent 
infection in the general population. This document gives 
guidance on the specific issues relating to the prevention of 
COVID-19 infection and the care of affected patients with 
kidney disease.
2. bACKGrOUND INFOrMAtION
CONsIDErED
2.1.  Virus-related issues
a.  It is a highly infectious virus with an R0 factor (the
number of new infections estimated to arise from a
single case) of approximately 3 (compared to influenza
with an R0 of approximately 1) [3]. Efforts to reduce the
spread may lower the R0 to < 1 in some areas.
b.  It is spread by droplets from the respiratory tract laden
with virus – this may contaminate fomites and surfaces.
Direct airborne spread may occur if a carrier is in close
proximity (< 2 metres) when droplets are expelled.
Aerosolised virus may persist for a period in the air but
the significance is not yet clear [4].
c.  Asymptomatic individuals may spread the virus although
the frequency of this is not known [5].
d.  Masks worn by infected persons may reduce environ-
mental contamination by viral particles [6].
e.  Virulence in an immune naïve population may result in
significant fatalities (0.5–5%). The mortality estimates
are affected by the testing strategy. Mortality rates may
be lower if undiagnosed, asymptomatic cases are
accounted for [7].
f.  Infection is currently diagnosed by nucleic acid detection
methods using a reverse transcriptase polymerase chain
reaction (RT-PCR) technique. Nasopharyngeal swabs
are currently preferred but sputum, tracheal aspirates or
broncho-alveolar lavage fluid (if available) are more
sensitive. Saliva may be an option in future. Negative
tests do not rule out infection completely and may need
to be repeated if the index of suspicion remains high [8].
2.2.  Patient-related issues
a. Asymptomatic infection is common [5].
b.  Mortality is higher in the elderly and patients with
comorbidities including hypertension, diabetes, asthma,
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a.   Many patients in this group are on angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin II receptor 
blockers (ARBs). It has been speculated that these 
increase the risk of complications, but this is unproven 
and has not been observed in clinical settings thus far. 
Patients should not stop their prescribed medicines, 
including ACE inhibitors or ARBs, unless indicated for 
other reasons [16,17]. Patients should have sufficient 
amounts of medicines to avoid frequent visits to clinics 
or pharmacies. If possible, medicines should be delivered 
to patients and several months' supply may be included 
where safe.
b.   Patients should practise social distancing, wear cloth 
masks on leaving home, practise hand hygiene as pre-
scribed by authorities and perform regular surface 
disinfection. 
c.   Patients should be educated about symptoms (see 
below). If symptomatic, they should call ahead to deter-
mine the procedures for triage and testing based on 
local protocols. 
d.   Routine visits to treating doctors should be curtailed 
and, where possible, replaced with telephonic or online 
consultation.
e.  Group activities should be cancelled.
f.   Patients on immunosuppression should not stop their 
medicines without discussion with treating physicians. It 
may be possible to reduce or change immunosuppres-
sive therapies based on the risk of the disease being 
treated. Patients with new or rapidly worsening disease 
may require ongoing or increased immunosuppres- 
sion [18,19].
g.   Acute kidney injury (AKI) is more common in patients 
with CKD. Patients should avoid nephrotoxic agents and 
drug doses should be modified during treatment for 
COVID-19.
h.   Psychological support may be needed to prevent anxiety, 
depression or other problems which could impact on 
adherence to therapy and patient well-being.
4.  CHrONIC HAEMODIALYsIs 
GUIDANCE
4.1.  Guidance for government authorities
Governments should include haemodialysis units in their 
integrated plans for dealing with the COVID-19 pandemic. 
These should include:
a.   Acknowledging the high risk of patients with kidney 
disease as noted above.
b.   Accommodation and concessions in lockdown regula-
tions to allow travel to and from treatment centres 
for patients and staff. 
c.   National, local and regional plans for different scenarios 
including dealing with isolated or high-volume outbreaks. 
These may include dedicated COVID-19 units and 
cohorting of patients.
d.   Ensuring adequate PPE provision to units dealing with 
COVID-19 in sufficient quantities to protect staff and 
optimize care of patients. Note the recent guidance 
from the Centers for Disease Control and Prevention 
(CDC) and World Health Organization (WHO) [20-
28]. See further guidance below.
e.   National guidelines on staff policies including non-
punitive, sick-leave policies and return to work policies 
should be formulated [25].
f.   National authorities should plan for an increase in 
demand for renal replacement therapy (RRT) related to 
AKI. This may require the acquisition of additional equip-
ment and the training of staff. International and regional 
cooperation with assistance from the African Associa-
tion of Nephrology (AFRAN) and the International 
Society of Nephrology (ISN) may be required to facili-
tate this. Equipment which can offer continuous or 
hybrid therapies is preferred. 
4.2.  Guidance for treatment centres [13,20, 
22-25]
Patient information and education
a.   Signage and information should be available to educate 
patients about COVID-19 and the triage processes in 
the unit. Signage must be prominent and easy to under-
stand, even by those with limited literacy.
b.   Patients should be educated on handwashing, sanitizing 
and masking procedures.
c.   Patients should be aware of symptoms and signs to look 
out for.
d.   Patients with symptoms should be aware of the pro-
cedures to follow.
All staff should receive detailed training on the following 
aspects:
a.   Understanding the basics of the disease including mecha-
nisms of spread.
b.   Recognizing symptoms and triage of suspected cases.
c.   Proper handwashing, sanitization and universal precau-
tions. These include handwashing with soap and water 
for at least 20 seconds or using a hand sanitizer which 
contains at least 60% alcohol. Avoidance of touching of 
the face should be emphasized.
d.   The importance of universal masking at all times by all 
patients and staff. Cloth masks for patients may be 
acceptable provided they conform to quality recom-
mendations as set out by local authorities. See CDC 
guidance at https://www.cdc.gov/coronavirus/2019-ncov/ 
prevent-getting-sick/diy-cloth-face-coverings.html [29].
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e.   Donning and doffing of PPE – see guidance from the 
CDC and WHO [24,26,27].
f.   Disinfection of surfaces and the environment as per 
protocols (see below).
g.   Unit protocols for suspected and confirmed cases (see 
below).
h.   “What do you do if you suspect you have been 
exposed?”
Procedures if a staff member is ill
Staff policy on sick leave should be non-punitive, to 
encourage staff to report their symptoms timeously. In 
severely staff-constrained settings, personnel who have 
been exposed may need to continue working while 
wearing masks and with adequate hand sanitization unless 
proven positive or symptomatic. Staff should not move 
between units.
staff facilities
Staff eating and common areas should not be filled to the 
point where physical distancing is not possible. This will 
require staggered mealtimes and the suspension of group 
activities or staggered group activities such as prayer and 
training.
All staff and patients should be screened daily for fever 
> 37.8°C.
Provision of PPE
Adequate supplies of PPE and cleaning equipment should 
be made available. See WHO and CDC guidance and 
recent advice from the Kenyan Renal Association [24,26, 
28]. Dialysis staff should employ standard contact and 
droplet precautions, including isolation gowns, gloves, 
masks, and eye protection (shields or goggles), as appro-
priate (Figure 1). Because PPE will need to be deployed for 
many weeks or months in this current pandemic, care must 
be taken to establish policies that will not exhaust the 
available supplies of these precious resources.
a.   Face masks – standard surgical face masks are acceptable 
if N95 masks are in short supply. These respirators 
should be prioritized for procedures that are likely to 
generate respiratory aerosols. Cloth masks or surgical 
masks should be used by patients and clinical personnel 
at all times in public spaces. 
b.   Eye protection – eye shields or goggles should be used 
by personnel caring for patients with COVID-19 to 
avoid droplet spread via the eyes. Reusable shields and 
goggles should be cleaned and disinfected according to 
manufacturers’ instructions. 
c.   Gowns – gowns or plastic aprons should be worn over 
laboratory coats, scrub suits or street clothes. If gowns 
are in short supply, they should be prioritized for 
Renal guidelines for COVID-19 in Africa
Figure 1.  CDC recommendations on acceptable PPE for healthcare workers caring for patients with COVID-19.
PrEFErrED PPE – UsE   N95 Or HIGHEr rEsPIrAtOr ACCEPtAbLE ALtErNAtIVE PPE – UsE   FACEMAsK
Face shield
or goggles
Face shield
or gogglesN95 or higher respirator
When respirators are 
not available, use the best 
alternative, like a facemask
Facemask
n95 or higher
respirators are 
preferred but 
facemasks are an 
acceptable alternative
Isolation gown Isolation gown
cdc.gov/COVID19
One pair
of clean,
non-sterile
gloves
One pair
of clean,
non-sterile
gloves
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initiating and terminating dialysis, manipulating access 
needles and catheters, assisting patients to and from the 
dialysis stations, and cleaning and disinfecting the dialysis 
station. 
d.  Shoe covers – these may be needed to prevent spread
via footwear to clean areas of the unit.
scenario planning by treatment centres
Treatment centres should have a detailed plan based on 
different scenarios they may face. Because of the variations 
in unit size, staffing, support structures and resources, this 
should be individualized and drawn up together with other 
local authorities and support groups. This will include 
policies on testing and contact tracing.
a.  Scenario planning based on numbers of expected cases
can differ.
b.  At the very least, the unit should plan for the following:
i.  A triage or screening process to identify suspected
or high-risk cases. This would include temperature
screening, symptom screening and eliciting a history
of contacts. This may be done prior to arrival at the
unit.
ii.   Separate waiting areas for suspected cases and
confirmed cases.
iii.   Spacing in waiting areas should allow for social
distancing. Patients should not arrive too early. They
may wait in cars or outside the building, depending
on the climate and available facilities. An SMS or
electronic notification system could be set up to
inform patients when their station is prepared.
iv.  An area where at-risk or suspected patients can
be dialysed, which is separated from other patients
or at least by 2 metres. Where possible, an isolated
negative pressure room is ideal (such as a non-
hepatitis B area).
v.   An area or time where confirmed COVID-19-
positive patients can be dialysed. Depending on
circumstances and numbers, this could take various
forms including a dedicated unit in the area, a
dedicated isolation area or a dedicated shift. At the
very least, the patient should be dialysed at the end
of the loop, separated by at least 2 metres from
other patients and nursed by a dedicated staff
member equipped with PPE.
Cleaning of dialysis machines, equipment and chairs [22, 
25,28,30,31]
a.  All dialysis machines, dialysis chairs, surrounding surfaces
and equipment must be disinfected with appropriate
cleaning agents. This includes BP cuffs and stethoscopes.
b.  Clean and disinfect frequently touched surfaces at least
thrice daily and after every shift. These include bedside
tables and lockers, dialysis machines, doorknobs, light 
switches, counter tops, handles, desks, phones, key-
boards, toilets, faucets and sinks, etc. 
c.  As most sphygmomanometer cuffs are now made of
artificial leather (Rexine), they should also be cleaned
using alcohol or hypochlorite-based (1% sodium hypo-
chlorite) solutions; however, the individual manufac-
turer’s manuals should be referred to.
d.  Individual cleaning cloths need to be used for cleaning
each machine and dialysis chair and discarded post
cleaning.
e.  Fresh water with appropriate disinfectant needs to be
used for cleaning each dialysis machine and chair. Water
must be flushed down the sluice when cleaning is
completed.
f.  Almost all common disinfectant solutions are effective
in killing the virus on surfaces. The key is effective and
frequent cleaning. It is recommended that solutions
for disinfection be composed either of hypochlorite,
alcohol, formaldehyde or glutaraldehyde, in accordance
with the manufacturer’s instructions.
g.   Cleaning-cloths and water should never be shared
among dialysis machines and chairs.
linen management [22,25,28,30,31]
a.  All onsite and offsite facilities that process or launder
linen for healthcare facilities must have documented
operating policies consistent with regulations.
b.  Handle all used linen with care to avoid dispersal of
microorganisms into the environment and to avoid
contact with staff clothing.
c.   Manage all linen used for a person suspected or
confirmed to have COVID-19 infection as for heavily
soiled linen.
d.  Wear a long-sleeved, fluid-resistant gown and disposable 
gloves during handling of soiled linen, to prevent skin
and mucous membrane exposure to blood and body
fluids.
e.  Remove the long-sleeved gown and disposable gloves
and perform hand hygiene following the handling of
used linen.
f.  Linen should be machine washed with a water temper-
ature > 60oC.
4.3.  Guidance for patients
4.3.1.  Patients should not miss dialysis sessions.
4.3.2.   Patients should be provided with the necessary 
documents/permits in the event of lockdowns or 
curfews.
4.3.3.   Patients should be educated about prevention 
strategies including:
a. Hand hygiene
115
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 b.  Cough etiquette
 c.  Avoiding touching the eyes, mouth and face
 d.   Avoiding symptomatic friends, family and col-
leagues
 e.  Masking in and out of the dialysis unit
 f.  Avoiding crowds and social distancing
 g.  Vaccination against influenza and pneumococcus
 h.   Avoiding travel and movement between dialysis 
units.
4.3.4.    Patients should self-screen for symptoms at home 
before each dialysis session.
4.3.5.    Signs and symptoms of COVID-19 include:
 a.  Fever
 b.  Cough
 c.  Diarrhoea 
 d.  Malaise 
 e.  Shortness of breath or difficulty breathing
 f.  Loss of smell or taste
 g.  Sore throat
 h.  Influenza-like illness
 i.  Some patients have no symptoms.
4.3.6.    Patients should advise if they have a recent travel 
history or exposure to a case of COVID-19.
4.3.7.    People who are older or have existing medical 
conditions, such as heart disease, lung disease or 
kidney disease, may be at higher risk of serious 
illness. 
4.3.8.    The usual vaccinations (hepatitis B, influenza, etc.) 
should be continued even in patients with COVID-19 
(https://apps.who.int/iris/bitstream/handle/ 
10665/331590/WHO-2019-nCoV-immunization_
services-2020.1-eng.pdf) [32].
4.3.9.    Patients with symptoms should be advised on the 
procedure of triage and testing.
4.3.10.  Patients should preferably not eat inside the dialysis 
units or waiting rooms. Some diabetic patients may 
require a snack to prevent hypoglycaemia.
4.3.11.  Patients should avoid shaking hands or sharing items.
4.3.12.  All patients requiring hospital admission should be 
tested for COVID-19 prior to or upon admission.
5.  DIALYsIs PrEPArEDNEss 
CHECKLIsts
Checklists can be used to assess preparedness of dialysis 
units for the triage and management of COVID-19 cases. 
Examples are available through the George Institute for 
Global Health [21,] and the CDC [33]. Alternatively, local 
authorities may create area-specific checklists using the 
guidance contained in this document. 
6.  sUGGEstED trIAGE MECHANIsM
6.1.   The goal of triage is to prevent spread of the disease 
in the dialysis unit to protect a vulnerable population. 
The risks of spread are aggravated by the following:
a.   The requirement for patients to aggregate at the 
dialysis unit in shifts, with difficulty separating them 
in time and space.
b.   The use of shared transport by patients.
c.   Asymptomatic carriage of the virus by staff and 
patients.
d.   The need for physical contact of patients with staff 
and equipment for treatment.
e.   The prolonged duration of treatment.
6.2.   A dedicated triage area (see Figure 2) outside the 
treatment area should be used for a risk check of the 
patient for the following:
a.  Positive contact or recent travel.
b.  Temperature check.
c.  Symptoms of COVID-19.
d.   If any of the above are of concern, the patient 
should be evaluated by a doctor and risk stratified. 
Further tests may be required.
6.3.   Patients and staff can be separated into three 
categories:
a.   Low risk – no symptoms, normal temperature, no 
risk factors. 
b.   Moderate risk – mild/nonspecific symptoms, tem-
perature 37.2–37.8°C, possible contact, normal 
tests such as ferritin, C-reactive protein (CRP), 
D-dimer, chest X-ray (CXR) or computed tomo-
graphy (CT) scan of the chest.
c.   High risk – specific symptoms, positive close 
contact, fever > 37.8°C, abnormal ferritin, CRP, 
D-dimer, CXR or chest CT scan.
6.4.   All patients and staff should wear a mask in all areas.
6.5.  Screening should include staff members.
6.6.  Low-risk patients may continue dialysis as usual.
6.7.  For moderate- and high-risk patients: 
a.   Check urea, creatinine and electrolytes, CRP, 
ferritin and D-dimer.
b.   Do nasopharyngeal swab test for PCR for SARS-
CoV-2.
c.   Perform CXR and check oxygen saturation.
d.   Dedicated COVID-19 units may be allocated in 
each region with sufficient staff and PPE.
e.   A dedicated area of the unit separated by at least 
2 metres from any other patient may be used, pro-
vided all patients are masked and the patient is 
nursed by a dedicated staff member with appro-
priate PPE.
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f.   A dedicated shift at the end of the day with full 
disinfection and terminal cleaning may be con-
sidered.
6.8.  Patients may be de-isolated [34]:
a.  If asymptomatic – 14 days after the positive result.
b.  If symptomatic – 14 days after clinical stability.
6.9.   Because of the need for ongoing contact after de-
isolation, repeat COVID-19 PCR testing may be 
appropriate. However, there is evidence that pro-
longed viral shedding is possible with patients not 
being infectious despite this [10].
6.10.   Staff who test positive should be removed from duty 
and can also be de-isolated as per the above 
guidelines.
7.  DIALYsIs PrEsCrIPtION IN CHrONIC 
HD PAtIENts WItH COVID-19
7.1.   The cytokine storm associated with raised IL6, IL18 
and IFN gamma is associated with poorer out- 
comes [35].
7.2.   Patients who are stable may continue with their 
chronic dialysis prescription and should not miss 
treatment sessions. High-flux dialysis membranes 
(with a sieving coefficient for myoglobin of > 0.5) are 
recommended for maximal dialysis efficiency. Careful 
attention to fluid balance and ongoing symptoma-
tology is required. Deterioration should trigger esca-
lation of therapy. Patients should be dialysed in a 
designated area [20].
7.3.   Patients with acute deterioration and those in an 
intensive care unit (ICU) should receive an individ-
ualized, daily dialysis prescription.
7.4.   Dialysis modalities used will depend on staff com-
petencies and the availability of equipment and con-
sumables. Centres should use modalities with which 
they are familiar.
7.5.   High-volume (> 35 mL/kg/h effluent) continuous 
haemofiltration (CVVHF) or haemodiafiltration 
(CVVHDF) may allow cytokine removal to alleviate 
cytokine storm-related complications [36,37].
7.6.   HDF may be preferred for intermittent treatments 
but no supporting data are available.
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Figure 2.  suggested screening and triage algorithm for dialysis units.
sCrEENING At HOME Or ON ArrIVAL FOr trEAtMENt
1. Fever, dyspnoea, cough, sore throat, malaise
2. Influenza-like illness
3. History of contact with a confirmed case of COVID-19
4. History of travel in the last 14 days
5. History of contact with patients with unexplained fever or respiratory symptoms
YEs
Do kidney function tests, and clinical assessment
Admit if required and follow inpatient protocols
Do nasopharyngeal swab for PCR for sARs-CoV-2
CXR (or CT scan, if available)
Do ferritin, CRP, D-dimer
Postpone dialysis if possible until results known
sARs-CoV-2 positive
sARs-CoV-2 negative
sARs-CoV-2 negative
Routine dialysis
Risk stratify
Retest in 48 hrs
Dialysis in preplanned space for persons under investigation
Full PPE and contact precautions
NO
Dialysis in preplanned unit 
or area
Full PPE and contact 
precautions
see text
sARs-CoV-2 positive
sARs-CoV-2 pending
Withold dialysis if 
safe until result 
known.
Dialysis if unsafe
HIgH RIsK
specific symptoms
Positive close contact
Fever (> 37.8ºC)
Abnormal ferritin, CRP, 
D-dimer, CXR or  
CT chest
MODERATE RIsK
Mild or nonspecific symptoms
Borderline temperature (37.2-37.8ºC)
Possible contact – not confirmed
normal ferritin, CRP, CXR or CT chest
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7.7.   Hybrid treatments like prolonged intermittent renal 
replacement therapies (PIRRT) and sustained low-
efficiency dialysis (SLED) may also be used in haemo-
dynamically unstable patients.
7.8.   See section on treatment of AKI for more informa- 
tion regarding dialysis prescriptions.
7.9.   Peritoneal dialysis may be safely employed as therapy 
even in acute settings. See section on AKI for further 
information [38].
8. CONtACt trACING [34]
8.1.   There is a paucity of high-quality evidence on this 
topic. Figure 3 shows examples of different scenarios. 
More information is available from the National 
Institute for Communicable Diseases (NICD) in South 
Africa [34].
8.2.  If a positive case is found:
a.  Close contacts of the case must be traced from at
least the time of first symptoms or 48 hours prior.
They include dialysis unit staff who had direct
contact with or nursed the patient without appro-
priate PPE. If the patient was masked at all times in
the unit, the risk to adjacent patients is smaller.
b.  Close contacts should be screened for symptoms
and asked to self-isolate. They should be tested if
appropriate. Staff may need to stay at home, if
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Figure 3.  Possible scenarios for dealing with exposed staff members (per nICD).
Abbreviations: ARI, acute respiratory illness; nICD, national Institute of Communicable Diseases of south Africa; PuI, Person 
under Investigation; HOD, Head of Department; nP/OP = nasopharyngeal/oropharyngeal; PPE, personal protective equipment.
self-isolate at home
sCENArIO 1:
worker with a positive 
COVID-19 test
sCENArIO 2:
worker with symptoms 
compatible with ArI
sCENArIO 3:
High risk + confirmed
COVID-19 exposure, 
worker asymptomatic
sCENArIO 4:
Low risk + suspected
COVID-19 exposure,
worker asymptomatic
Place on sick leave
(disinfect workspace if 
applicable)
line manager to assess and 
confirm COVID-19 
exposure risk
line manager to assess
COVID-19 exposure risk
Assess validity of
symptoms by health
professional
ARI
symptoms: 
refer for 
sARs-CoV-2 
testing
sARs-CoV-2 
positive: 
follow
scenario 1
Does not 
qualify
as PuI: 
follow
usual sick 
leave 
procedures
All tests 
negative:
follow usual 
sick leave
procedures
Case reported to nICD
and Dept of labour  
if applicable
If confirmed high-risk
exposure, HOD to approve
self-quarantine
For low-risk exposure or 
contact with suspected 
COVID-19 case, person 
continues to work but  
self-monitors temperature 
and symptoms for 14 days
Return to work 14 days
after symptom onset
(mild cases)
self-quarantine at home for 
minimum 7 days
Daily symptom self-check 
until 14 days since last 
COVID-19 exposure If index case tests negative 
for COVID-19,  
no action neededReturn to work 14 days
after clinical stability 
e.g. after oxygen is stopped
(severe cases) Evaluate for early return 
to work on day 8 post-
exposure with testing on 
nP/OP samples. If negative 
and well, return to work and 
follow work restrictions
Report incident to nICD
line manager/Occupational 
health obtains possible index 
case’s COVID-19 test  
result urgently
If possible COVID-19 
symptoms develop, follow 
scenario 2
If index case is COVID-19 
positive, but person wore 
full PPE, continue to work 
and self-monitor for 14 days
If possible COVID-19 
symptoms develop,  
follow scenario 2
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resources allow, until testing can occur. A risk-
based assessment can be carried out based on 
type of contact and presence of symptoms. A line 
manager should be delegated to decide on type 
of risk.
c.   The optimal time for testing is not known, although 
it is recommended that testing be done upon 
symptom onset or 5–7 days after contact.
8.3.   If the RT-PCR test is negative, follow the proposed 
guidelines in Figure 3.
9.  strAtEGIEs rEGArDING COVID-19 IN 
PD PAtIENts [39]
This is the summary of guidelines issued by the International 
Society of Peritoneal Dialysis, which can be accessed at 
https://ispd.org/strategies-covid19/. 
People on PD should stay at home. Hospital visits should 
be undertaken only for urgent indications (for example, 
suspected peritonitis). Consultations should otherwise be 
conducted using telehealth. If needed, consultations should 
be timed to avoid long periods in a waiting area. All patients 
should wear a mask when outside their homes.
1.   Normal universal precautions and handwashing must 
be applied everywhere at all times. Surface disinfec- 
tion should be regularly carried out.
2.   Continued education and training of staff about 
COVID-19 is recommended for every PD unit. Self-
monitoring for COVID-19 for individual healthcare staff 
members and screening tests for suspected cases is 
recommended.
3.   At home, patients should have at least 2 weeks of PD 
supplies and sufficient medications in case they must 
self-isolate, or if there is a break in the supply chain.
4.   In the PD unit, non-essential procedures, for example 
PET or clearance measurements, should be avoided to 
minimize unnecessary patient contact.
5.   Patients should be educated regarding symptoms of 
the disease. 
6.   Patients should be advised also to call in rather than 
present unannounced to units if they are symptomatic 
or have been in contact with a confirmed case.
7.   Once determined as having had potential exposure 
to the virus, or COVID-19-related symptoms, patients 
should have the necessary viral swab tests by a desig-
nated team, depending on local practice. 
8.   Elective and non-urgent admissions should be resched-
uled, and inpatient elective surgical and procedural 
cases should be delayed.
9.   For PD patients with confirmed disease, barrier mea-
sures must always be applied. This includes self-isola-
tion at home. If patients need help with performing 
PD, caregivers should wear PPE.
10.   Mildly or moderately ill COVID-19-positive patients 
can continue PD treatment as usual, with prescription 
adjustment according to evaluation.
11.   Severely or critically ill COVID-19-positive patients 
requiring life support due to multiple organ dysfunction 
syndrome can be temporarily transferred to automated 
peritoneal dialysis or to haemodialysis.
12.   Precautionary measures for PD staff performing in-
hospital dialysis is essential. 
13.   Personal protective equipment should be available for 
all members of the PD team. 
14.   Universal hygiene measures must be strictly observed 
by healthcare staff. 
15.   In hospitals, effluent from PD bags should be discarded 
as medical waste. At home, patients may discard the 
fluid in the toilet (preferably after adding bleach to the 
fluid or the toilet). Aerosols can be generated by toilet 
flushes, so the toilet lid should be shut before flushing. 
Uninfected persons should not do this without wearing 
PPE. Bags can be double-bagged and kept for three 
days before discarding [40].
10.  GUIDELINEs FOr MANAGEMENt 
OF AKI IN tHE CONtEXt OF COVID-19 
INFECtION
Figure 4 is a suggested management algorithm for patients 
with AKI in the context of COVID-19 [41].
10.1.  Definition of AKI [42]
Kidney Disease Improving Global Outcomes (KDIGO) 
defines AKI as any of the following:
•   Increase in serum creatinine by 0.3 mg/dL (26.5 μmol/L) 
or more within 48 hours or
•   Increase in serum creatinine to 1.5 times baseline or 
more within the last 7 days or
•   Urine output less than 0.5 mL/kg/h for 6 hours. 
KDIGO has also recommended a staging system for the 
severity of the AKI (Table 1).
10.2.  Pathophysiology and burden of AKI 
associated with COVID-19
AKI is more common among patients with more severe 
disease, particularly in ICU settings, and is considered a 
negative prognostic factor with respect to survival [11,43, 
44]. It is thought that a maladaptive systemic inflammatory 
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Figure 4.  Management protocol for acute kidney injury in patients with COVID-19 infection (adapted from the Egyptian 
Ministry of Health guidelines, with permission).
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; RRT, renal replacement therapy; CRRT, continuous renal
replacement therapy; HDF, haemodiafiltration; slED, sustained low-efficiency dialysis; PD, peritoneal dialysis; sCr, serum creatinine; 
us, ultrasound.
Assessment of kidney function
MANAGEMENt PrOtOCOL FOr AKI PAtIENts WItH COVID-19 INFECtION
AKI 
Increase in sCr by ≥ 0.3 mg/dl within 48 hrs
Increase in sCr to ≥ 1.5 times baseline within 7 days
Decrease in urine volume to < 0.5 ml/kg/h for 6 hrs
CKD (history, exam, lab,  
imaging and criteria for CKD)
Monitor high risk patientDiagnostic work up
AKI staging
AKI stage 1AKI stage II & IIIPost-renal
urology consult
ICu admission  
if indicated
Pre-renal & renal
Continue diagnostic 
work up
Continue diagnostic 
work up
RRT if indicated
CRRT*
HDF (high flux membrane) or
slED (high flux membrane) or
slED (low flux membrane) or
Acute PD
- depending on availability
nB: *If patient surge overwhelms the CRRT capacity, treat for 8–12 hours instead of continuously 
and use higher flow rates of 40–50 ml/kg/hour.
Continue 
diagnostic  
work up
Manage 
underlying cause
Drug dose adjustment
Abd/pelvic usObstructive uropathy
HIgH-RIsK PATIEnT
Age ≥ 65 years
CKD
Chronic diseases  
(heart, lung, liver)
Diabetes mellitus
Cancer
sepsis
Circulatory shock
Major cardiac and  
non-cardiac surgery
nephrotoxic drugs,  
e.g. nsAIDs
Radiocontrast agents
Dehydration
Discontinue all  
nephrotoxic drugs
Ensure volume status
Ensure perfusion pressure
Monitor functional 
haemodynamics
Alternatives for radiocontrast 
procedures
Monitor sCr and urine output
Conservative AKI on top of CKD
YEs
YEs
nO
nO
table 1.  KDIgO classification of acute kidney injury [42]. 
stage serum creatinine urine output
I
1.5–1.9 times baseline 
or 0.3 mg/dL (26.5 µmol/L) increase
mL/kg/h for 6 h
II    2–2.9 times baseline mL/kg/h for 12 h
III
3 times baseline 
or 4 mg/dL (354 µmol/L) increase 
or initiation of renal replacement therapy
0.3 mL/kg/h for 24 h
or 
anuria for 12 h
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immune response, in the face of a cytokine storm, 
contributes to hypoperfusion-related injury of the renal 
tubules [35,37].
Some evidence suggests the possibility of a direct cytopathic 
effect of SARS-CoV-2. ACE 2 and members of the serine 
protease family, essential for viral uptake by host cells, are 
highly expressed on podocytes and tubular epithelial cells. 
Reports of albuminuria and haematuria in the setting of 
COVID-19, along with isolation of viral RNA from the 
urine, further supports potential viral tropism for the 
kidney [45].
AKI is common in the ICU setting, affecting up to 40% of 
patients, with a frequent need for dialysis [46-48]. Approx-
imately 5% of hospital admissions require dialysis [48].
Inevitably, the question arises whether RRT should be 
approached differently in the acute care setting. If a cytokine 
storm is contributing to disease severity in COVID-19, then 
in theory convective-based clearance may be superior for 
removal of large-sized cytokines compared to diffusion-
based modalities. While this argument has been made 
repeatedly in the management of sepsis, clinical evidence 
has been, at best, inconclusive [36].
Possible mechanisms by which COVID-19 patients may 
develop AKI include:
a. Pre-renal: hypovolaemia, cardiogenic or septic shock
b.  Tubular: acute tubular injury (ischaemic or toxic), ACE
2-mediated
c. Interstitial: drug-induced
d.  Vascular: renal vein thrombosis, thrombotic micro-
angiopathy
e.  Glomerular: collapsing glomerulopathy (not proven)
f. Post-renal factors.
10.3.  Management of AKI in COVID-19 
patients
Risk factors and comorbidities must be assessed. These 
include advanced age, smoking, diabetes mellitus, chronic 
obstructive airways disease, chronic liver or kidney disease, 
congestive heart failure and history of radiocontrast 
administration or other medicines that affect kidney 
function.
Fluid resuscitation
The need for prompt fluid resuscitation to restore 
euvolaemia and systemic haemodynamics in septic patients 
is well established. Growing evidence suggests that the 
cardiac output does not always increase in many critically ill 
patients when challenged with a fluid bolus. 
a.  The exact amount and precise timing of tapering such
resuscitation is not established. With regard to AKI, fluid
resuscitation is based on the theory that restoration of
circulating volume will improve renal perfusion [49].
b.  The improvement of haemodynamic macrovascular
parameters may result in the restoration of cortical
renal perfusion but this does not occur in all cases of
septic shock [50].
c.  Fluids are not different from drugs and carry side effects
such as the activation of cytokines, shedding of the
capillary glycocalyx and adversely affecting the capacity
of the kidney to adequately filter excess fluid and
nitrogenous waste.
d.  The recently released “hour-1 bundle” recommends
that fluid resuscitation should be performed in septic
patients with hypotension or lactate ≥ 4 mmol/L with
30 mL/kg of crystalloids [51].
e.  In adult patients admitted to the ICU with sepsis, a
positive fluid balance after the first day was associated
with an increased risk of AKI. Fluid overload increases
mortality. Excess fluid has been shown to be a negative
predictor for recovery of renal function [52,53].
f.   Current international guidelines from the Surviving
Sepsis Campaign recommend crystalloids for initial
resuscitation and subsequent volume replacement, with
albumin “when patients require substantial amounts of
crystalloids”. However, the debate on which type of
fluid to use in the resuscitation phase is still open. A
recent meta-analysis reported that crystalloids were less
effective than colloids in stabilizing resuscitation end-
points such as mean arterial pressure, cardiac index and
central venous pressure [54].
g.  Finally, evidence supporting albumin use in patients with
septic shock comes from the ALBIOS study in which
albumin administration was used to replenish albumin
instead of using it for treating hypovolaemia [55].
10.4.  Dialysis modalities
Depending of the availability of the modality and/or trained 
personnel, the available modalities for RRT are:
a. Continuous renal replacement therapy (CRRT)
b.   Prolonged intermittent renal replacement therapy
(PIRRT) or slow low-efficiency dialysis (SLED) with high
flux filters
c.  Intermittent haemodialysis (IHD) with high flux filters
d.  Peritoneal dialysis (PD) either as continuous ambulatory
peritoneal dialysis (CAPD) or automated peritoneal
dialysis (APD) or intermittent peritoneal dialysis (IPD).
The use of acute peritoneal dialysis can be lifesaving and
should be considered in settings where haemodialysis
is not available [56,57].
10.5.  Patient and staff care 
a.   Nephrologists, dialysis and ICU staff should follow
national guidelines for infection control for COVID-19
infection, that is, adopting PPE and safety guidelines
during their interactions with patients [26,57].
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b.   Nephrologists should consider minimizing/avoiding daily 
contact with patients by collaborating with primary 
physicians – for example, the ICU physician if patient is 
admitted to their unit – and relying on them to convey 
relevant findings, such as volume status. 
c.   Indications to start RRT are as for other patients with 
AKI. 
d.   Accumulating evidence suggests that a delayed RRT 
initiation is safe [58].
e.   Loop diuretics may be used in the management of 
volume overload, according to the treating physician’s 
discretion. 
f.    If there is a lack of dialysis or ICU nurses, non-dialysis or 
non-ICU nurses may be recruited to monitor patients 
undergoing RRT, under the supervision of an ICU or 
dialysis nurse [57].
g.   For patients on chronic PD, the dialysis can be continued 
as APD in hospital, to reduce the exposure of nursing 
staff. If volume control cannot be maintained with 
PD, the patient may need temporary haemodialysis [56, 
57,59].
h.   It is essential that contact precautions and guidelines in 
the use of PPE are adhered to at all times.
10.6.  Vascular access
If a patient develops indications to start dialysis – or if a 
patient on chronic HD needs vascular access – a double-
lumen internal jugular catheter (preferably) should be 
inserted. If this is not possible, a subclavian or femoral 
catheter may be used. This should be placed by the 
physician with the most expertise in placement of central 
venous catheters, e.g. a vascular surgeon, ICU physician or 
radiologist [32]. Ultrasound-guided placement is recom-
mended, where available. Jugular catheters are more 
convenient when a patient needs to be in the prone posi-
tion to facilitate ventilation.
10.7.  Care and disinfection of dialysis 
equipment 
a.   CRRT filter changes can be performed every 72 hours. 
If the need exceeds the number of machines available, 
shorter periods (e.g. 12 hours) may be attempted using 
higher flow rates (40–50 mL/kg/h).
b.   After treatments, dialysis equipment should be dis-
infected according to national guidelines. The equipment 
should be disinfected before being removed from the 
room. Additional cleaning may be needed before the 
machine can be used for another patient [57].
10.8.  Crrt and sLED in the ICU
The preferred modalities for RRT in critically ill patients are 
continuous renal replacement therapies (CRRT) or sus-
tained low-efficiency dialysis (SLED) and other hybrid 
treatments (PIRRT) [37,57]. CRRT is a commonly initiated 
treatment in the ICU. Indications include AKI with metabolic 
acidosis, hyperkalaemia, excessive uraemia or refractory 
fluid overload. 
10.9.  suggested prescription
a.   Modalities used will depend on the availability of staff 
and equipment and the clinical complexity of the case. 
b.   CVVH pre- and/or post-dilution with a prescribed dose 
25–30 mL/kg/h (to obtain an administered dose 20–25 
mL/kg/h). In the presence of a cytokine storm higher 
doses may be required. The dose should be regularly 
reassessed to determine if treatment goals are being 
met [47].
c.   CRRT is beneficial for maintenance of volume balance, 
haemodynamic stability, and to allow adequate nutri-
tional support. It will improve the clearance efficiency 
of medium-sized and small molecular toxins and can 
maintain body temperature. CRRT is particularly indi-
cated in patients with AKI who are suspected to 
have high levels of cytokines and with haemodynamic 
instability.
d.   If a patient surge overwhelms the CRRT capacity at 
an institution, consideration should be given to using 
CRRT machines for prolonged intermittent treat- 
ments – for example 10 hours instead of continuous – 
with higher flow rates – such as 40–50 mL/kg/h – and 
then using the machine for another patient, after 
cleaning as per institutional policies.
e.   Prolonged intermittent or SLED techniques are not 
inferior to continuous therapies. High-flux membranes 
are essential, if available, in this context.
f.   Advantages of SLED include its use in haemodynamically 
unstable patients, the ability to use equipment for 
multiple patients, reduced requirements for anticoagu-
lation, lower cost and wider availability.
g.   Intermittent (standard duration) haemodialysis can be 
used in stable patients.
h.   High-quality water generated by reverse osmosis should 
be used for all therapies.
10.10. Anticoagulation
Patients with COVID-19 have a high risk of thromboem-
bolic events and many centres use higher dosages of 
thrombosis prophylaxis than usual (often double-dose) [60, 
61]. The choice of anticoagulation is based on the patient’s 
need for systemic anticoagulants, the risk or presence of 
bleeding, and the available drugs and expertise. Choices 
include:
a.  Regional citrate anticoagulation, where available.
b.  Systemic heparinization with unfractionated heparin.
c.  Treatment without using anticoagulants.
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Many COVID-19-infected patients requiring intensive care 
management show altered liver function values. This may 
be secondary to drug-induced hepatotoxicity as well as due 
to possible liver involvement. This is associated with an 
increased risk for citrate accumulation.
10.11.  Drug modification in COVID-19 
patients undergoing dialysis [62]
Dose adjustments should be discussed between the pri-
mary physician, the nephrologist and the clinical pharmacist. 
Note that these are not treatment recommendations.
a.   Anti-viral therapy: no adjustment of dose required – 
for example, lopinavir/ritonavir, darunavir/ritonavir, 
darunavir/cobicistat.
b.   Hydroxychloroquine (note that there is no clear 
evidence of efficacy and some safety concerns have 
been raised): for CRRT no dose adjustment is required; 
for haemodialysis or peritoneal dialysis, administer 50% 
of the dose and monitor ECG for detection of QT 
prolongation.
c.   Ribavirin: use not recommended in severe renal dys-
function.
11.  GUIDELINEs FOr KIDNEY 
trANsPLANt rECIPIENts [63]
Kidney transplant patients taking immunosuppression are at 
higher risk of complications from COVID-19 [64]. Infor-
mation about this disease and its impact on transplanta- 
tion is evolving rapidly, so the guidance may change over 
time. Many of the recommendations are based on 
experience with the CMV and BK viruses.
11.1.  Epidemiology
Data on transplant patients are limited but increasing [64-
68]. The lymphocyte count is lower in those who require 
ICU care. It is not possible to tell if lymphopaenia is a 
manifestation of a more severe form of disease, or if it is a 
predisposing factor for severe disease. Many transplant 
recipients have medication-induced lymphopaenia. Close 
attention should be paid to transplant patients with 
suspected or confirmed COVID-19 infection who are 
lymphopaenic [69].
11.2.  recommendations
11.2.1  Transplant programmes
a.   All transplant-related teams should develop plans to 
reduce the burden on the healthcare system and to 
mitigate against an interruption in the care of transplant 
patients. 
b.   Temporary suspension of the living-donor kidney trans-
plant programmes should be considered when dona-
tion can safely be deferred to a later date. This can be in 
consultation with local authorities.
c.   If transplantation is required as a life-saving procedure, 
it can be conducted with appropriate assessment of 
donor and recipient risk, and with appropriate informed 
consent. 
d.   The continuation of deceased-donor programmes will 
depend on local guidelines. High rates of in-hospital 
infection with COVID-19, especially with reduced bed 
availability, may necessitate temporary suspension of 
the programmes. A decision on whether to continue 
with surgery may need to be made whenever a donor 
becomes available.
e.   SARS-CoV-2 should be excluded in donors and 
recipients [70].
11.2.2 Transplant centres
a.   Visits to outpatient clinics that are not critical should 
be either deferred or substituted with telemedicine. 
b.   Visitors to transplant wards should be restricted as much 
as possible. 
c.   Determine who can work remotely and ensure they 
have the resources to do so. 
d.   Develop messaging for patients about how and when 
to contact the transplant centre in case of illness. 
e.   Develop guidance for candidates and recipients about 
risk mitigation, including limiting exposure to large 
crowds, hand hygiene and avoidance of sick people. 
f.    Staff and facilities should be prepared to receive sus-
pected or confirmed cases of COVID-19. 
g.   Guidance for which transplant recipients need evalua-
tion, testing and management by the transplant centre, 
versus which can remain at home with close remote 
follow-up, should be developed. 
h.   Staff with respiratory symptoms should stay at home 
(national policies should be applied). 
i.   Testing of staff should be done according to national and 
local guidelines. 
j.   Prevention policies and procedures: national, local and 
institutional guidelines should be followed [57].
11.2.3 Transplant donors 
a.   In the case of a diagnosis of COVID-19 infection, the 
donor must be excluded from donation for at least 
three months. If the need for donation is urgent, then 
this can be considered on a case-by-case basis after at 
least 28 days from diagnosis. 
b.   In the case of close contact with a person diagnosed 
with SARS-CoV-2 infection, the donor shall be excluded 
from donation for at least 28 days. The donor should be 
closely monitored for the presence of COVID-19. 
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c.  In the case of travel to high-risk areas for COVID-19
infection or being in close contact with a person
travelling from such an area, the donor shall be excluded
from donation for at least 28 days.
d.  Donors within 28 days before donation should practise
good hygiene (WHO recommendations) and avoid
crowded places and large gatherings [13,71].
11.2.4 Transplant recipients 
a. Transplant recipients should avoid travel.
b.  Transplant recipients with higher risk of infection include
those having had contact with COVID-19-infected
people or contact within 14 days prior to the onset of
the disease, those with a history of travel within the
previous 14 days and those in contact with patients
who have fever or respiratory symptoms
c. They should avoid elective clinic visits.
d.   Transplant recipients with risk factors or suspicious
symptoms should be instructed to call the transplant
centre and avoid presenting to the clinic without noti-
fication to avoid inadvertent exposures.
e.   They should be examined and evaluated according
to local policies to exclude or confirm SARS-CoV-2
infection [68,71].
11.3.  Management of immunosuppressive 
medication [63,68,71]
Figure 5 is a proposed algorithm for the adjustment of 
immunosuppression in patients infected with SARS-CoV-2.
a.  Asymptomatic, stable patients with no knowledge of
COVID-19 status require no change of immuno-
suppressive medication.
b.  Mild disease (mild upper respiratory symptoms, tem-
perature < 38°C and no dyspnoea, persistent chest
pain or intensive cough, oxygen saturation on room air
> 95%, respiratory rate < 25/min, no evidence of
pneumonia on chest CT scan):
•  For patients on triple therapy: stop mycophenolic
acid (MPA)/azathioprine (AZA)/mTOR inhibitors
(mTORi) and maintain dual therapy with calcineurin
inhibitors (CNI) and steroids.
•  On dual therapy: continue this. If dual therapy is a
steroid-free regimen with CNI + MPA/mTORi, con-
sider replacing MPA/mTORi with low-dose steroids.
If on MPA+mTORi, consider replacing MPA or
mTORi with low-dose steroids.
•  Consider CNI dose reduction (to the lower bound of
the therapeutic range according to the immunological
risk) if there is no clear improvement over the first
3–5 days.
c.  Mild COVID-19 pneumonia (oxygen saturation 94–95%
in room air, respiratory rate 25–29/min):
•  High-risk patient: (age 70+, risk factors such as dia-
betes, cardiac or pulmonary disease, heavy smoking,
BMI > 30 kg/m2, eGFR < 30 mL/min/1.73 m2, lym-
phocyte depletion therapy within previous 3–6
months) – stop MPA/AZA/mTORi, stop CNI,
increase (or start) steroids to 15–25 mg/day.
•  Not high-risk patient: stop MPA/AZA/mTORi,
maintain on dual therapy CNI-steroids. Reduce the
cyclosporine dose to target trough levels of 50 ±
15 ng/mL and tacrolimus levels of 3 ± 1 ng/mL. Con-
tinue steroids in maintenance dose.
d.  If anti-retroviral (lopinavir/ritonavir) treatment is neces-
sary, stop CNI (to avoid severe drug interactions) and
monitor as shown in Figure 5.
e.  More severe COVID-19 pneumonia (oxygen saturation
< 94% in room air, respiratory rate ≥ 30/min, unstable
or deteriorating course or requiring non-invasive venti-
lation or transfer to the ICU):
•  Discontinue all immunosuppressive drugs, if possible.
Increase/start steroids at 15–25 mg/day (or higher
according to local practice). Carefully consider
continuing with low-dose CNI in patients with higher
risk of rejection [57].
11.4.  When to resume immunosuppressive 
therapy
A proposed approach in severely ill patients is to resume 
the CNI at half of the previous dosage, starting at least 3 
days after clinical resolution and after two negative swabs 
(one at discharge and one 3 days later), with the aim of 
gradually reaching a trough level of 3–5 ng/mL of tacrolimus 
or 200–300 ng/mL of cyclosporine at the second hour 
(C2). Resumption of full-dose CNI dosage and mainte-
nance of the prednisolone can be considered after 15 days 
free of symptoms and an additional negative swab. Case-
by-case evaluation for re-initiation of MPA, AZA and 
mTORi is needed [72].
11.5.  Drug interactions
a.   There is a possible increase in the exposure of
cyclosporine, tacrolimus and mTOR inhibitors with
chloroquine/hydroxychloroquine. It is advised to moni-
tor the trough levels of cyclosporine, tacrolimus and
mTORi in this setting [62].
b.   Patients starting anti-retroviral drugs that contain
ritonavir or cobicistat must stop mTORi and CNIs. If
the aim is to continue tacrolimus, it should be admini-
stered only when blood levels are < 5 ng/mL and the
dose should not exceed 0.5 mg (overall dose reduction
to one-fifth or lower). Cyclosporine should be given
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only when levels are below 50 ng/mL (overall dose 
reduction to one-fifth or lower, administered once a 
day) [62].
c.  Administration of azithromycin should be accompanied
with monitoring of cyclosporine levels. Azithromycin
may cause increased cyclosporine concentrations
through glycoprotein inhibition and/or competition for
biliary excretion [62].
12. CONCLUDING rEMArKs
These guidelines on COVID-19 and the kidney were 
commissioned by the executive committee of the African 
Association of Nephrology and represent a major colla-
borative effort by African nephrologists. They should be of 
practical value across the African continent and beyond.
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Figure 5.  Proposed algorithm for the adjustment of immunosuppression in patients infected with sARs-CoV-2 (adapted from 
the Egyptian Ministry of Health guidelines, with permission).
Abreviations: RR, respirarory rate; AZA, azathioprine; CnI, calcineurin inhibitor; CsA, cyclosporine; mTORi, mTOR inhibitor;  
MPA, mycophenolic acid; TAC, tacrolimus.
At home or in triage area
1. Temp ≥ 37.3ºC, complaint of fever, cough, dyspnoea, sore throat or common cold or influenza
2. In contact with COVID-19 infected persons or within 14 days prior to the onset of their disease
3. History of travel within 14 days
4. In contact with patients who have fever or respiratory symptoms
MODULAtION OF IMMUNOsUPPrEssIVE MEDICAtION FOr KIDNEY trANsPLANt PAtIENts 
DUrING tHE COVID-19 PANDEMIC
nB: Restrict follow-up in 
stable kidney transplant 
patients at outpatient clinic
CXR, CT chest, laboratory tests for COVID-19
suspicious case of waiting for results
High-risk patient
Confirmed COVID-19
self or room isolation 
and repeat after 48 h
no change of  
immunosuppressive therapy
YEs
YEs
YEs
nO
nO
MIlD DIsEAsE (HOME)
no symptoms suggestive of pneumonia
O2 > 95% at room air, RR < 25/min
no evidence of pneumonia on imaging
MODERATE DIsEAsE (HOsPITAl)
Evidence of mild pneumonia
O2 > 94-95% at room air, RR 25-29/min 
suspicious lesions on lung imaging
sEVERE DIsEAsE (HOsPITAl)
Evidence of more severe pneumonia
O2 > 94% at room air, RR ≥ 30/min 
unstable or deteriorating course
Transfer to the intensive care unit (with or 
without mechanical ventilation)
Discontinue all immunosuppressive drugs
Increase/start steroids at 15-25 mg/day  
or higher
Higher risk of rejection
Consider to continue with low dose CnI
Triple therapy: stop MPA/AZA/mTORi, 
maintain on dual therapy CnI-steroids
Dual therapy: continue dual therapy
Dual therapy (steroid-free regimen): for 
CnI + MPA/mTORi, replace MPA/mTORi 
with low dose steroids
MPA + mTORi, replace MPA/mTORI  
with low-dose steroids
no clear improvement over 
the first 3–5 days
CnI dose reduction
stop MPA/ 
AZA/mTORi
stop CnI
Increase (or 
start) steroids
stop MPA/AZA/
mTORi
Dual therapy 
CnI-steroids
Reduce CnI levels to 
target  
(CsA: 50 ± 15 ng/ml)
(TAC: 3 ± 1 ng/ml)
Continue steroids in 
maintenance dose
lopinavir/
Ritonavir
stop CnI and 
monitor
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